Lenvatinib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AIFA (Italy), AOTMIT (Poland) and G-BA (Germany), among others, recommended or restricted lenvatinib, while CIPM (Spain) did not recommend it.
On the same population the two systems disagree outright: NICE (England) recorded restricted in TA858, while PBAC (Australia) recorded not recommended for “Advanced renal cell carcinoma (RCC)”.
HAS (France) has been harder on lenvatinib than on its own caseload: it refused 2 of 5 decisive submissions here (40%), against a base rate of 11% across everything it has assessed.
Assessment has run over 10.4 years, from 2015 at PBAC (Australia) to 1 Dec 2025 at DMC (Denmark).
PHARMAC (New Zealand) changed its position: recommended on 25 Feb 2021, restricted by 25 Feb 2021.
Every one of the eight highest-volume agencies in this archive has a record for lenvatinib.
The file is active: 10 of 49 records date from 2023 or later.
The programme is broad: 16 distinct indication wordings are recorded for lenvatinib by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
7 of these 49 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
PBAC (Australia) was first to assess lenvatinib, in 2015; ZIN (Netherlands) did not open a file until 15 May 2023 — a wide spread of 7.8 years between the earliest and latest system to look at it.
The record arrives in waves: 10 separate years each carry two or more decisions, spread across 10 years in total.
13 of the 14 agencies here assessed lenvatinib more than once, PBAC (Australia) most often at 7 entries — repeat review is the norm for this molecule rather than the exception.
lenvatinib has been through 14 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for lenvatinib reads 20 recommended, 10 not recommended, 6 restricted and 5 no benefit, with 8 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| NYE METODER (Norway) | 27 Apr 2025 | Kombinasjonsbehandling med everolimus til voksne pasienter med avansert nyrecellekarsinom etter en tidligere vaskulær en… | decision recorded | source |
| DMC (Denmark) | 23 Apr 2025 | Fremskreden eller recidiverende endometriekarcinom, som har sygdomsprogression med eller efter tidligere behandling med … | Anbefalet | source |
| CIPM (Spain) | 26 Sep 2024 | Indicaciones terapéuticas autorizadas: Kisplyx está indicado para el tratamiento de adultos con carcinoma de células ren… | not financed by the SNS · art. 92 e | source |
| ZIN (Netherlands) | 6 Jul 2023 | Pakketadvies sluisgeneesmiddel lenvatinib (Lenvima®) voor de behandeling van baarmoederkanker | reimbursed | source |
| AIFA (Italy) | 12 Nov 2019 | è indicato come monoterapia per il trattamento del carcinoma epatocellulare (Hepatocellular Carcinoma, HCC) avanzato o n… | fully innovative status not granted · reimbursed class H | source |
44 further decisions for lenvatinib, across 14 agencies, are not shown here. They include the most recent record on file, 1 Dec 2025 from DMC (Denmark); its outcome is in the subscriber dataset. They link to 35 further source documents.
Related molecules
- cabozantinib — divergent outcome (recommended vs not recommended) on a shared indication
- tivozanib — divergent outcome (recommended vs restricted) on a shared indication
- atezolizumab — same ATC class L01X — Antineoplastics
- olaparib — same ATC class L01X — Antineoplastics
- durvalumab — same ATC class L01X — Antineoplastics
- aflibercept — same ATC class L01X — Antineoplastics
Coverage: 49 decisions for lenvatinib from 14 agencies, 2015 to 2025. Data to 7 Sep 2026. ATC class L01X — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.